White Paper
In the white paper, industry leaders Validic, Biogen, Pfizer, and Medidata discuss how digital health is disrupting the way the pharmaceutical industry gathers data from clinical trial participants. By arming participants with wearable and FDA Class II medical devices, sensors, and applications, pharma and CROs can remotely collect activity data along with key biometrics.
This stands to significantly restructure the drug development process, allowing companies to bring a drug to market more efficiently and cost-effectively while also improving the clinical trial participants’ experience.
Pharmaceutical companies looking to implement a digital health strategy can download this free white paper today to: